Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04413305
Other study ID # KY2019-429KP
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 28, 2020
Est. completion date September 30, 2021

Study information

Verified date May 2020
Source Huashan Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study is to investigate the effect of the infection control measures based on the active screening of carbapenem-resistant Klebsiella pneumoniae and whole-genome based tracking and surveillance though the hospital.


Recruitment information / eligibility

Status Recruiting
Enrollment 1000
Est. completion date September 30, 2021
Est. primary completion date September 30, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

1. The patient was admitted to the ICU of neurosurgery in the west hospital of huashan hospital affiliated to fudan university from September 2019 to September 2021, or transferred from the ICU of another hospital

2. The patient is more than 18 years old and less than 80 years old, regardless of gender.

3. Informed consent of the patient;

Exclusion Criteria:

1. Patients participating in other clinical trials at the same time

2. Pregnant

4. People who will affect the outcome of the study: whose specimens could not be received or not enough for testing

Study Design


Intervention

Other:
screen of CRKP and infection control measure
For intervention group, we screen admitted patients for carbapenem-resistant Klebsiella pneumoniae and carry out 'Bundle' infection and control measures. When outbreak or tranmission of CRKP was observed, we take whole-genome sequencing to track origin and transmission route to decease CRKP rate.

Locations

Country Name City State
China Infectious department of Huashan Hospital, Fudan University Shanghai

Sponsors (2)

Lead Sponsor Collaborator
Huashan Hospital Sumitomo Pharmaceuticals (Suzhou) Co. Ltd

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluate the influence of WGS-based screen and control measures on the CRKP occurrence rate 2 years
Secondary Analysis of transmission pattern and route pre and post WGS-based tracking 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT03598543 - Epidemiology of Klebsiella Pneumoniae in China
Completed NCT04959344 - Safety and Immunogenicity of a Klebsiella Pneumoniae Tetravalent Bioconjugate Vaccine (Kleb4V) Phase 1/Phase 2
Not yet recruiting NCT03245632 - Epidemiological Characteristics and Treatment Protocol for Carbapenem-Resistant Klebsiella Pneumoniae in China N/A
Recruiting NCT03891433 - Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic UTI Due to -ESBL-producing Enterobacteriaceae Phase 4